Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET

被引：70

作者：

Dunphy, Mark P. S. ^{[1
]}

Lewis, Jason S. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA

来源：

JOURNAL OF NUCLEAR MEDICINE | 2009年 / 50卷

关键词：

PET; therapy monitoring; hypoxia; steroid receptors; proliferation; POSITRON-EMISSION-TOMOGRAPHY; ASSESSING TUMOR HYPOXIA; ADVANCED BREAST-CANCER; AMINO-ACID-TRANSPORT; EVENT-FREE SURVIVAL; PROSTATE-CANCER; IN-VIVO; ESTROGEN-RECEPTOR; BRAIN-TUMORS; C-11-METHIONINE PET;

D O I：

10.2967/jnumed.108.057281

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

This review article discusses PET agents, other than F-18-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic intervention. This review deals primarily with non-F-18-FDG PET tracers that are in the final stages of preclinical development or in the early stages of clinical application for monitoring the therapeutic response. Four sections related to the nature of the tracers are included: radiotracers of DNA synthesis, such as the 2 most promising agents, the thymidine analogs 3'-F-18-fluoro-3'-deoxythymidine and F-18-1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)thymine; agents for PET imaging of hypoxia within tumors, such as Cu-60/62/64-labeled diacetyl-bis(N-4-methylthiosemicarbazone) and F-18-fluoromisonidazole; amino acids for PET imaging, including the most popular such agent, L-[methyl-C-11]methionine; and agents for the imaging of tumor expression of androgen and estrogen receptors, such as 16 beta-F-18-fluoro-5 alpha-dihydrotestosterone and 16 alpha-F-18-fluoro-17 beta-estradiol, respectively.

引用

页码：106S / 121S

页数：16

共 189 条

[91] Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluorestradiol (FES) [J].

Mankoff, DA ;

Tewson, TJ ;

Eary, JF .

NUCLEAR MEDICINE AND BIOLOGY, 1997, 24 (04) :341-348

[92] Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma [J].

Matthay, KK ;

Edeline, V ;

Lumbroso, J ;

Tanguy, ML ;

Asselain, B ;

Zucker, JM ;

Valteau-Couanet, D ;

Hartmann, O ;

Michon, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2486-2491

[93]

MAUREA S, 1994, J NUCL MED, V35, P1429

[94] Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals [J].

Maurer, RI ;

Blower, PJ ;

Dilworth, JR ;

Reynolds, CA ;

Zheng, YF ;

Mullen, GED .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (07) :1420-1431

[95] Improved synthesis of anti-[18F]FACBC:: improved preparation of labeling precursor and automated radiosynthesis [J].

McConathy, J ;

Voll, RJ ;

Yu, WP ;

Crowe, RJ ;

Goodman, MM .

APPLIED RADIATION AND ISOTOPES, 2003, 58 (06) :657-666

[96]

MCELVANY KD, 1982, J NUCL MED, V23, P425

[97]

MCGUIRE AH, 1991, J NUCL MED, V32, P1526

[98] BREAST-CANCER - PET IMAGING OF ESTROGEN-RECEPTORS [J].

MINTUN, MA ;

WELCH, MJ ;

SIEGEL, BA ;

MATHIAS, CJ ;

BRODACK, JW ;

MCGUIRE, AH ;

KATZENELLENBOGEN, JA .

RADIOLOGY, 1988, 169 (01) :45-48

[99] Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice:: Comparison of 2′-deoxy-2′-[18F]fluoro-D-glucose (FDG) and 3′-[18F]fluoro-3′-deoxythymidine (FLT) [J].

Molthoff, Carla F. M. ;

Klabbers, Bianca M. ;

Berkhof, Johannes ;

Felten, Jasper T. ;

van Gelder, Marcelle ;

Windhorst, Albert D. ;

Slotman, Ben J. ;

Lammertsma, Adriaan A. .

MOLECULAR IMAGING AND BIOLOGY, 2007, 9 (06) :340-347

[100] Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer [J].

Monazzam, Azita ;

Josephsson, Raymond ;

Blomqvist, Carl ;

Carlsson, Joergen ;

Langstrom, Bengt ;

Bergstrom, Mats .

BREAST CANCER RESEARCH, 2007, 9 (04)

← 5 6 7 8 9 10 11 12 13 14 →